Ever Supreme Bio Technology Co

Ever Supreme Bio Technology Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Ever Supreme Bio Technology Co (6712.TWO) as of Nov 3, 2026 is 27.83. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 33.90 — a change of -17.92% (lower).

EV/OCF

27.83

YoY

-17.92%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Ever Supreme Bio Technology Co is 2025 27.83 . EV/OCF (Enterprise Value to Operating Cash Flow) of Ever Supreme Bio Technology Co was 2024 33.90 . It decreases by -17.92% lower compared to the previous year.

The Ever Supreme Bio Technology Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-195.44 TWD
Jan 1, 2019
-118.33 TWD
Jan 1, 2020
-105.10 TWD
Jan 1, 2021
100.35 TWD
Jan 1, 2022
42.84 TWD
Jan 1, 2023
32.24 TWD
Jan 1, 2024
33.90 TWD
Jan 1, 2025
27.83 TWD
The Ever Supreme Bio Technology Co EV/OCF history
YEAREV/OCFYoY
27.83-17.92%
33.90+5.16%
32.24-24.74%
42.84-57.31%
100.35-195.48%
-105.10-11.18%
-118.33-39.45%
-195.44-56.75%
-451.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ever Supreme Bio Technology Co Stock analysis

What does Ever Supreme Bio Technology Co do? Ever Supreme Bio Technology Co., Ltd. generates revenue through the research, development, and sale of stem cell products. The company's primary products include ADCV01, an autologous dendritic cell tumor vaccine currently in phase II clinical trials in Taiwan, and UMSC01, a human allogeneic umbilical cord stem cell product approved by the FDA for clinical phase I in the United States and undergoing similar trials in Taiwan for myocardial infarction treatment. UMSC01 is also being evaluated for acute ischemic stroke therapy in the United States under FDA phase I clinical trials. The firm targets medical institutions and healthcare providers in Taiwan and the United States for its stem cell therapies, focusing on cardiovascular and neurological conditions. The company's revenue streams are derived from the development and commercialization of its stem cell product pipeline, with ADCV01 and UMSC01 representing key assets in its portfolio. UMSC01's dual approval status in the U.S. and Taiwan positions it as a significant product for both markets. Ever Supreme Bio Technology plans to expand its offerings by developing mesenchymal stem cells for multiple sclerosis treatment, aiming to enter new therapeutic segments in the future. Ever Supreme Bio Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Supreme Bio Technology Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Ever Supreme Bio Technology Co is 27.83 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Ever Supreme Bio Technology Co changed from 33.90 to 27.83, representing a -17.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Ever Supreme Bio Technology Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Ever Supreme Bio Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Ever Supreme Bio Technology Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Ever Supreme Bio Technology Co